KUKU

KU ScholarWorks

  • myKU
  • Email
  • Enroll & Pay
  • KU Directory
    • Login
    View Item 
    •   KU ScholarWorks
    • Dissertations and Theses
    • Theses
    • View Item
    •   KU ScholarWorks
    • Dissertations and Theses
    • Theses
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Discovery of Novel Inhibitors of Cellular Efflux by High-Content Screening with a Fluorescent Mimic of Taxol

    Thumbnail
    View/Open
    Available after: 2021-08-31 (2.645Mb)
    Issue Date
    2019-08-31
    Author
    Smith, Tomas Joseph
    Publisher
    University of Kansas
    Format
    116 pages
    Type
    Thesis
    Degree Level
    M.S.
    Discipline
    Medicinal Chemistry
    Rights
    Copyright held by the author.
    Metadata
    Show full item record
    Abstract
    Fluorescence-based assays play key roles in drug discovery and development. These assays are widely used due to the widespread availability of fluorescent probes and highly sensitive detection platforms. This method is a mainstay of high-throughput drug screening (HTS) campaigns, where simple and inexpensive assays are preferred for scalability and repeatability. This approach can identify novel chemotypes that may lead to new methods to treat disease. To develop a new phenotypic assay for drug discovery, we investigated a fluorescent mimic of the anticancer drug Taxol, termed Pacific Blue-Gly-taxol (PBGT). This molecular probe binds cellular microtubules and is a highly sensitive substrate of the cellular efflux transporter P-glycoprotein (P-gp). When HeLa cervical carcinoma cells are cotreated with PBGT (1 μM) and the P-gp inhibitor verapamil (25 μM), cellular fluorescence increases by ~ 10-fold as analyzed by confocal microscopy or flow cytometry. Because of the simplicity and sensitivity of this assay of P-gp activity, we envisioned that it could be optimized in a 96-well plate format to provide a useful method to investigate cellular efflux mediated by this protein transporter. To provide a proof of concept, 1584 diverse compounds obtained from the National Cancer Institute (NCI) were screened using automated pipetting and flow cytometry. The primary screen yielded more than 23 hit compounds with equivalent or of higher activity than verapamil (25 μM). Among these hits, we identified diarylureas that do not appear to associate directly with P-gp but rather disrupt the typical rod-like structure of mitochondria. These compounds may inhibit P-gp indirectly by affecting mitochondria or via a target that additionally affects this organelle. These results demonstrate that PBGT is a highly sensitive probe for discovery of inhibitors of P-gp and may allow identification of alternative mechanisms of inhibition of this major drug transporter.
    URI
    http://hdl.handle.net/1808/29848
    Collections
    • Medicinal Chemistry Dissertations and Theses [80]
    • Theses [3908]

    Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.


    We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.


    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    Browse

    All of KU ScholarWorksCommunities & CollectionsThis Collection

    My Account

    Login

    Statistics

    View Usage Statistics

    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    The University of Kansas
      Contact KU ScholarWorks
    Lawrence, KS | Maps
     
    • Academics
    • Admission
    • Alumni
    • Athletics
    • Campuses
    • Giving
    • Jobs

    The University of Kansas prohibits discrimination on the basis of race, color, ethnicity, religion, sex, national origin, age, ancestry, disability, status as a veteran, sexual orientation, marital status, parental status, gender identity, gender expression and genetic information in the University’s programs and activities. The following person has been designated to handle inquiries regarding the non-discrimination policies: Director of the Office of Institutional Opportunity and Access, IOA@ku.edu, 1246 W. Campus Road, Room 153A, Lawrence, KS, 66045, (785)864-6414, 711 TTY.

     Contact KU
    Lawrence, KS | Maps